Folate receptor alpha as a tumor target in epithelial ovarian cancer. Kalli Kimberly R,Oberg Ann L,Keeney Gary L,Christianson Teresa J H,Low Philip S,Knutson Keith L,Hartmann Lynn C. Gynecologic Oncology . 2008
Epithelial ovarian cancer (EOC) is the deadliest gynecological cancer, and presents a major clinical challenge due to limited treatment option
Folate receptor alpha (FRα) is a promising biomarker and therapeutic target for ovarian, breast, brain, lung, and colorectal cancers.3,4,5,6,7,8Our previous work in large clinically relevant breast cancer cohorts demonstrated substantial FRα expression at the level of both mRNA (The Cancer ...
Elevated folate receptor alpha (FRα) expression is characteristic of epithelial ovarian cancer (EOC), thus establishing this receptor as a candidate target for the development of novel therapeutics to treat this disease. Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate (ADC) th...
Bart, The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer, Cell Oncol. (Dordr.) 35 (2012) 9-18.Crane LMA, Arts HJG, Oosten MV, et al.The effect of chemo- therapy on expression of folate receptor-alpha in ovarian can- cer[J ].Cellul Oncol, 2012,35 (...
The efficacy of HAdV-C5-based OV is hampered by a lack of tumour selectivity, where the primary receptor, hCAR, is commonly downregulated during malignant transformation. Conversely, folate receptor alpha (FRα) is highly expressed on ovarian cancer cells, providing a compelling target for tumour...
folate receptor–negative cells. A phase I trial of mirvetuximab soravtansine revealed that the agent was well tolerated, and in a small expansion cohort of ovarian cancer (n= 17), 53% had an objective response despite platinum-resistant disease. This agent may undergo further development, ...
The drug appears to have anti-proliferative and cytotoxic effects on tumour cells over expressing FR-alpha. Phase II of the trial consists of its testing as a single-agent and in combination with standard-of-care chemotherapy (carboplatin and taxane) in platinum-sensitive ovarian cancer patients ...
Ovarian cancer is a common gynecological cancer world-wide and contributes to the highest mortality despite of advances in treatment modalities. There is increasing evidence that diet is a crucial factor in the development and progression of various human cancers. While folate is an essential nutrient...
Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecologic Oncology, 108(3), 619–626. Article CAS PubMed PubMed Central Google Scholar Bagnoli, M., Canevari, S., Figini, M., Mezzanzanica, D., Raspagliesi, F., Tomassetti, A., et al. (2003). A step ...